Investigation of activity of jnk kinases new potential inhibitors

A. L. Zagayko, O. A. Krasilnikova, Mohamed Ahmed Musmari

Abstract


JNK kinase - group stress-activated kinases that are involved in apoptosis, growth, development and differentiation of cells. JNK kinase activation is observed in the development of inflammatory processes, neurodegenerative disorders, insulin resistance, some types of cancer. Therefore, the search for new inhibitors of kinases JNK is an important and urgent problem. The purpose of this study was to investigate the activity of the new compounds, potential inhibitors of JNK kinases. Experiments were performed on isolated rat hepatocytes.  It was determined the content of JNK  and its active phosphorylated form (p-JNK), the activity of glycogen synthetase (GS) and alanine aminotransferase (ALT). It was found that substances G0003, G0004, G0006 and G0007 inhibited the activity of JNK, reducing the content of p-JNK, decreased GS activity and increased ALT activity. We have found that substances G0006 and G0007 showed the highest activity.


Keywords


JNK kinase; glycogen synthase; ALT; hepatocytes; acetaminophen

References


Ahmad A. Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling / A. Ahmad, S. H. Sarkar, A. Aboukameel et al. // Carcinogenesis. – 2012. – vol. 33, N 12. – P.2450-2456.

Assi K The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis / K. Assi, R. Pillai, A. Gómez-Muñoz et al. // Immunology. - 2006. – vol. 118, N 1. – P. 112-112.

Bogoyevitch M. A. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases / M. A. Bogoyevitch, B. Kobe // Microbiol Mol Biol Rev. – 2006. – vol. 70, N 4. – P. 1061-1095.

Cubero F. J. Combined Activities of JNK1 and JNK2 in hepatocytes protect against toxic liver injury / F. J. Cubero, M. E. Zoubek, W. Hu et al. // Gastroenterology. - 2016. – vol. 150, N 4. – P. 968-981.

Dickens M. A cytoplasmic inhibitor of the JNK signal transduction pathway / M. Dickens, J. S. Rogers, J. Cavanagh et al. // Science. – 1997. – vol. 277, N 5326. – P. 693–696.

Frame S. GSK3 takes centre stage more than 20 years after its discovery / S. Frame, P. Cohen // Biochem J. - 2001. – vol. 359, N 1. – P. 1-16.

Gao D. The Effects of palmitate on hepatic insulin resistance are mediated by NADPH oxidase 3-derived reactive oxygen species through JNK and p38MAPK pathways / D. Gao, Sh. Nong, X. Huang et al. // J Biol Chem. – 2010. – vol. 285, N 39. – P. 29965–29973.

Gehringer M. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014) / M. Gehringer, F. Muth, P. Koch et al. // Expert Opin Ther Pat. – 2015. – vol. 5, N 8. – P. 849-872.

Hanawa N. Role of JNK Translocation to Mitochondria Leading to Inhibition of Mitochondria Bioenergetics in Acetaminophen-induced Liver Injury N. Hanawa, M. Shinohara, B. Saberi et al. // J. Biol. Chem. - 2008. – vol. 283, N 20. – P. 13565–13577.

Kaneko M. Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis (alkoxymethyl)-K-252a derivatives / M. Kaneko, Y. Saito, H. Saito et al. // J Med Chem. – 1997. – vol. 40. – P. 1863–1869.

Karin M. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance / M. Karin, E. Gallagher // IUBMB Life. – 2005. - vol. 57, N 4-5. – P. 283-295.

Kockeritz L. Glycogen synthase kinase-3—an overview of an over-achieving protein kinase / L. Kockeritz, B. Doble, S. Patel et al. // Curr. Drug Targets. - 2006. – vol. 7, N 11. – P. 1377-1388.

Larsen A. K. Naringin-sensitive phosphorylation of plectin, a cytoskeletal cross-linking protein, in isolated rat hepatocytes / A. K. Larsen, M. T. Møller, H. Blankson et al. // J Biol Chem. – 2002. – vol. 277, N 38. – P. 34826-34835.

Morimitsu Y. Inhibitory effect of flavonoids on sulfo- and glucurono-conjugation of acetaminophen in rat cultured hepatocytes and liver subcellular preparations / Y. Morimitsu, N. Sugihara, K. Furuno // Biological and Pharmaceutical Bulletin. – 2004. - vol. 27, N 5. - P. 714-717.

Peti W. Molecular basis of MAP kinase regulation / W. Peti, R. Page // Protein Sci. - 2013. – vol. 22, N 12. – P. 1698-1710.

Samuel V. T. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease / V. T. Samuel, Z. X. Liu, L. Qu et al. // J Biol Chem. – 2004. – vol. 279, N 31. – P. 32345-32353.

Seki E. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches / E. Seki, D. A. Brenner, M. Karin // Gastroenterology. – 2012. – vol. 143, N 2. – P. 307-320.

Shinohara M. Silencing Glycogen Synthase Kinase-3β inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence / M. Shinohara, M. D. Ybanez, S. Win et al. // J Biol Chem. – 2010. – vol. 285, N 11. – P. 8244–8255.

Zhang J. Y. The role of the c-Jun N-terminal kinase signaling pathway in skin cancer / J. Y. Zhang, M. A. Selim // Am J Cancer Res. -2012. –vol. 2, N 6. - 691-698.

Zhou Y. Y. MAPK/JNK signalling: a potential autophagy regulation pathway / Y. Y. Zhou, Y. Li, W. Q. Jiang et al. // Biosci Rep. - 2015. – vol. 35, N 3. - e00199.

Gehringer M. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014) / M. Gehringer, F. Muth, P. Koch et al. // Expert Opin Ther Pat. – 2015. – vol. 5, N 8. – P. 849-872.

Cubero F. J. Combined Activities of JNK1 and JNK2 in hepatocytes protect against toxic liver injury / F. J. Cubero, M. E. Zoubek, W. Hu et al. // Gastroenterology. - 2016. – vol. 150, N 4. – P. 968-981.


GOST Style Citations






DOI: https://doi.org/10.24959/90036

Abbreviated key title: Ukr. bìofarm. ž.

ISSN 2519-8750 (Online), ISSN 2311-715X (Print)